Serum Uric Acid
Conditions
Keywords
Serum uric acid, Pancreatic cancer, Pancreaticoduodenectomy, Distal pancreatectomy
Brief summary
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
Detailed description
Serum uric acid is a risk factor for gallbladder cancer in men and has a strong effect on pancreatic cancer in women. It has also been shown that elevated intracellular serum uric acid can induce an inflammatory stress response, which may promote its transformation, while elevated extracellular serum uric acidy further stimulate tumor cell proliferation, migration, and survival, and promote the development of highly aggressive cancer. In this study, the changes of serum uric acid before and after surgery was used as a prognostic marker for the survival of pancreatic cancer patients.
Interventions
DIAGNOSTIC_TESTserum uric acid test
Detect the serum uric acid in blood sample
Sponsors
Hepatopancreatobiliary Surgery Institute of Gansu Province
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Patients with pathologically confirmed pancreatic cancer (primary) * Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy） * The postoperative survival time was at least 6 weeks
Exclusion criteria
* No surgery was performed, or only palliative surgery/ biopsy was performed * Patients who underwent emergency hemodialysis or plasma exchange after surgery * History of gout or long-term urate-lowering therapy, such as allopurinol * Patients are missing follow-up data * Hydrochlorothiazide and furosemide were used * Chronic kidney disease * Oncolytic syndrome * Hemolytic anemia * Lead poisoning * Hyperparathyroidism * Hypothyroidism * A tyrosinase inhibitor was used * Patients with nonpancreatic primary tumors * Pregnant or postpartum women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 3-5 years | Overall survival was defined as the time from diagnosis to death. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cost of hospitalization | 3 months | The cost of the first hospitalization from admission to discharge. |
| Length of hospital stay | 3 months | The first day of hospitalization for the first admission to the last day of discharge. |
| Pancreatic fistula | 3 months | Whether or not pancreatic-intestinal anastomotic leakage occurred at the time of the first hospitalization. |
| Recurrence-free survival | 3-5 years | Recurrence-free survival is the length of time from either the date of diagnosis or the start of therapy for a disease to the date of the first loco-regional or systemic recurrence. |
| Bleeding | 3 months | Whether or not there was bleeding after the first inpatient surgery. |
| Abdominal cavity infection | 3 months | Whether or not there was an abdominal infection after the first inpatient surgery. |
| Biliary fistula | 3 months | Whether or not a biliary-intestinal anastomotic leak occurred at the time of the first hospitalization. |
Countries
China
Contacts
Primary ContactWenbo Meng, M.D. Ph. D.
Backup ContactZhengping An, M.D.
Outcome results
None listed